Rigel Pharmaceuticals, Inc.
RIGL
NASDAQ·Healthcare·Biotechnology·Mkt cap $900.5M
$48.67
▲ +0.35%
P/E
2.97
Mkt Cap
$900.5M
52-Wk Range
$24.95–$52.24
52-Week Range
$24.95 - $52.24
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 19.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Approved commercial product (Tavalisse) generating revenue and market validation
- Strategic partnerships with tier-one pharmaceutical companies (AstraZeneca, Eli Lilly, Daiichi Sankyo) providing development capital and commercialization expertise
- Focused pipeline targeting underserved rare immune and hematologic diseases with limited competitive alternatives
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Tavalisse market expansion and label expansion opportunities in chronic immune thrombocytopenia
Value
Trading at 0.6x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+61.8% over 3m
Quality
Excellent
High-growth business (3% revenue growth, 91% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying RIGL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of $0.88 vs $0.09 consensus (+903.9% surprise). Revenue of $78.7M vs $55.3M expected (+42.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+903.9%
Revenue trend · last 8Q
—
+61%
+81%
+176%
+26%
+21%
+10%
-23%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$55.3M
$57.6M
$53.3M
$101.7M
$69.5M
$69.8M
$58.8M
$78.7M
Margins · last 8Q
Gross
89.2%
Operating
29.9%
Profit
22.0%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 17, 2026
vs Industry
How RIGL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related